Drug Reference

Sofosbuvir / Velpatasvir

Antivirals for treatment of HCV infections

Fact box

Therapeutic class: Antivirals for treatment of HCV infections

Brand names

Epclusa

Available as

400 MG · Oral Tablet200 MG · Oral Tablet150 MG200 MG

Multi-ingredient product

SofosbuvirVelpatasvir

This medicine contains more than one active ingredient. To avoid attributing one component’s information to the whole product, structured label sections aren’t shown here — see the component pediatric notes below and the full combination label on DailyMed.

Current FDA labels (DailyMed)

SOFOSBUVIR AND VELPATASVIR (VELPATASVIR AND SOFOSBUVIR) TABLET, FILM COATED [ASEGUA THERAPEUTICS LLC]
EPCLUSA (VELPATASVIR AND SOFOSBUVIR) TABLET, FILM COATED EPCLUSA (VELPATASVIR AND SOFOSBUVIR) PELLET [GILEAD SCIENCES, INC.]

8 marketed products on record (RxNorm)

Authoritative sources

DailyMed — current FDA labeling →
LactMed — breastfeeding safety (NLM) →
MedlinePlus — plain-language drug info →
RxNorm (NLM) →

Reference only — not clinical advice. Verify against current FDA labeling and consult a licensed provider. About half of pediatric drug use is off-label and is not reflected in FDA labels; absence of pediatric information does not mean a medicine is unused or unsafe in children.